Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Clayton Russell, holds the title of Chief Medical Officer at Larimar Therapeutics, Inc..
On 2026-11-16, the insider transacted 3,322 shares.The shares were transacted at a weighted average price of $3.01 per share, resulting in a total market-relevant value of $10K.
Clayton Russell (Chief Medical Officer) bought $10K of $LRMR
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.